BASi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. We provide world-class research to the global pharmaceutical industry. Our services include preclinical toxicology, bioanalysis and a full range of pharmaceutical analysis services. BASi also manufactures innovative scientific instruments including the Culex® Automated In Vivo Sampling System which can collect blood, bile, and more from awake, freely-moving subjects. We are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on time.

1. Corporate Overview 2013
BASi | Corporate Overview

2. BASi | Corporate Overview 2
Who We Are
• BASi is a drug development services firm that helps
pharmaceutical and biotech companies navigate the
complex drug development process.
• We operate along the entire drug development
continuum; however, we provide our clients with unique
technical skills and services from Discovery to Clinical
Proof-of-Concept.
• In addition, we help our clients to meet their key
milestones on time and frequently for less money than
it would cost them with internal resources.

3. BASi | Corporate Overview 3
What We Believe In
Technical Capability
• We have the qualifications to get the job done
Trustworthiness
• We understand the importance of the data we provide
Client Centric
• We get the job done right the first time, on time
Collaborative
• We communicate frequently to make the best decisions
Energetic
• We are eager to find solutions to our client’s complex
problems

4. BASi | Corporate Overview 4
Corporate Headquarters
West Lafayette, IN
Preclinical Services
Evansville, IN
Indianapolis
• 120,000ft2
• Bioanalysis
• Discovery
• Pharmaceutical analysis
• Formulation Stability
• Product R&D
• Immunochemistry
• Manufacturing
• 90,000ft2
• Preclinical Toxicology
• Pathology

5. BASi | Corporate Overview 5
Basic Post
Research Discovery Pre-Clinical Clinical Approval
Phase 1 | Phase 2 | Phase 3 NDAIND
In Vivo & In Vitro Discovery
• ADME-PK/PD
• BASi-developed Culex® Automated In Vivo
Sampling
• Simultaneous collection of multiple data
streams
Toxicology
• Pre- and Post-IND Studies
• General toxicology services (Acute, Chronic)
• Carcinogenicity studies
• Immunotoxicology and biomarkers
• Pharmacokinetics and drug metabolism
Bioanalysis
• LC-MS/MS analytical platforms
• Immunoassay
• High throughput and fast turnaround analysis
• GLP/GCP compliant
• History of successful regulatory audit (FDA, MHRA)
• 21-CFR-Part11 compliant systems including Watson LIMS
Pharmaceutical Analysis
• NDA, IND and Q stability
• Experts in method development and validation
• Final product release and testing
• Dosing solutions analysis
• Compendial testing
• In Vitro bioequivalence
• GLP- and cGMP-compliant
• Any dosage form, medical devices or
combination

6. BASi | Corporate Overview 6
• MS Platforms: Sciex, Micromass, Finnegan TSQ
• TomTec Quadra 96 platforms
• UPLC systems – Waters Acquity® and Shimadzu Nexera®
• CTC and Shimadzu multi-plate autosamplers
• UV-Vis, fluorescence, EC, CAD
• SpectraMax® M5 Microplate Readers
• MesoScale Discovery ECL detector
Method Development, Validation,
and Sample Analysis Utilizing:
Contract Bioanalytical Services

7. BASi | Corporate Overview 7
• Bioanalytical support for domestic and international studies
• Clinical and non-clinical studies
• Proprietary and non-proprietary drugs
• Exogenous and endogenous (biomarkers) assays
Sample Analysis

8. BASi | Corporate Overview 8
Sample Types
• Plasma, serum, whole blood, urine, bile, milk
• Dried Blood Spots
• Tissues: kidney, lung, brain, muscle, spleen,
coronary band, artery and others
• Microdialysate
• In vitro test system: hepatocyte, media
• Different species: human, mouse, rat, dog, pig,
monkey, rabbit, etc.

9. BASi | Corporate Overview 9
• Acute, Subchronic, Chronic
Toxicology
• Carcinogenicity
• Clinical Pathology
- Hematology
- clinical chemistry,
urinalysis
- coagulation assays
- specimen processing
- biomarkers
• Necropsy and
Histopathology
Preclinical Services

10. BASi | Corporate Overview 10
Pharmaceutical Analysis Capabilities
• GLP and cGMP Compliant
• Method development and validation
• NDA, IND, and QC Stability
• Final product release
• In-Vitro Bioequivalence
• Compendial testing
• Dosing solution analysis
• Formulation stability
• Analysis of various dosage forms,
including devices and combination
products
• Licensed for all schedules of
controlled substances

11. BASi | Corporate Overview 11
• Macromolecule PK
• Anti-drug antibody assay (immunogenicity)
• Biomarkers
• Method development, validation and sample
analysis
Immunoassay Services

12. BASi | Corporate Overview 12
Mass Spectrometers
• Sciex, Micromass, Finnegan TSQ
• HPLC, UHPLC, Waters Acquity®, Shimadzu
Nexera®
• UV, Fluorescence, photodiode array,
electrochemical and CAD detectors
• TomTec Quadra 96 platforms
• CTC and Shimadzu multi-plate autosamplers
• SpectraMax® M5 Microplate Readers,
MesoScale Discovery ECL detector
• Triturus® Automated Immunoanalyzer
Bioanalytical Equipment

13. BASi | Corporate Overview 13
Key Bioanalytical Staff
• 45 total staff members (11 PhD)
• R&D Group (MD) – 5 staff (2 PhD, 1 MS)
• Bioanalytical Production – 20 staff (7 PhD)
• Mass Spec Group – 2 staff (2 PhD)
• Sample Management - 5 staff
• Metrology - 3 staff
• Quality Control & Assurance - 7 staff
• Report writing and document management (3 staff)

14. BASi | Corporate Overview 14
Sampling Pump
Empis ® Infusion Pump
Refrigerated Sample
Storage
Raturn®
Telemetry
Metabolic Waste Collection
• Freely moving,
Non-stressed subjects
• No manual handling
• 24hr operation
• Wireless notification
• Quiet operation
• IR Sample detection
• Better data
• Lower cost
• Better decisions
Automated In Vivo
Sampling System

15. BASi | Corporate Overview 15
Regulatory Compliance and
Quality Assurance
• Our culture is focused on
protecting our exemplary
regulatory record which
includes
– no findings
– voluntary actions for
corrections
• Your samples and data are
safe in our hands
• Our European operations are
reviewed by the FDA and the
Medicines and Healthcare
Products Agency

16. BASi | Corporate Overview 16
Senior Leadership
Lori Payne
VP
Analytical & Discovery
Services
Phillip Downing
Sr. Director
Preclinical Services
Candace Johnson
Director
Instruments &
Manufacturing
Jill Lynn
Director
Human Resources and
Security
Jacquelyn M. Lemke
President & CEO

17. BASi | Corporate Overview 17
• Contact
Ron Zimmerman, Jr.
Business Development Manager
rzimmerman@BASinc.com
(765) 497-5822 direct
(765) 414-0937 cell